Comparison of Baseline Characteristics and Survival Between Patients With Idiopathic and Connective Tissue Disease-related Pulmonary Arterial Hypertension

Journal of Heart and Lung Transplantation

Volumn 28, Issue 6, 2009, Pages 621-627

  Ruiz Cano, Maria J ^a   Escribano, Pilar ^a   Alonso, Rafael ^a   Delgado, Juan ^a   Carreira, Patricia ^a   Velazquez, Teresa ^a   Sanchez, Miguel A Gomez ^a   Sáenz de la Calzada, Carlos ^a  

^a Cardiology Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CARBON MONOXIDE; ILOPROST; PROSTACYCLIN; UNIPROST;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEMODYNAMICS; HUMAN; IDIOPATHIC DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SJOEGREN SYNDROME; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; WALKING;

EID: 65749102801     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.02.016     Document Type: Article

References (45)

1. Simonneau G., Galiè N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 suppl 1 (2004) S5-S12
2. Morse J.H., Antohi S., Kasturi K., et al. Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome. Scand J Immunol 51 (2000) 607-611
3. Gurubhagavatula I., and Palevsky H.I. Pulmonary hypertension in systemic autoimmune disease. Rheum Dis Clin N Am 23 (1997) 365-394
4. Salerni R., Rodnan G.P., Leon D.F., et al. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 86 (1977) 394-399
5. Yousem S.A. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 21 (1990) 467-474
6. Stupi A.M., Steen V.D., Owens G.R., et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29 (1986) 515-524
7. Pietra G.G., Edwards W.D., Kay J.M., et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80 (1989) 1198-1206
8. Kawut S.M., Taichman D.B., Archer-Chicko C.L., et al. Pulmonary arterial hypertension related to systemic sclerosis. Chest 123 (2003) 344-350
9. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
10. Koh E.T., Lee P., Gladman D.D., et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35 (1996) 989-993
11. MacGregor A.J., Canavan R., Knight C., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 40 (2001) 453-459
12. Fisher M.R., Mathai S.C., Champion H.C., et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 54 (2006) 3043-3050
13. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-302
14. Galiè N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary artery hypertension. N Engl J Med 353 (2005) 2148-2157
15. Kulkarni A., Singh T.P., Sarnaik A., et al. Sildenafil for pulmonary hypertension after heart transplantation. J Heart Lung Transplant 23 (2004) 1441-1444
16. Chua R., Keogh A., and Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 24 (2005) 498-500
17. Williams M.H., Das C., Handler C.E., et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92 (2006) 926-932
18. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 (1987) 216-223
19. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998. In: Rich S. (Ed). World symposium on primary pulmonary hypertension (1998), World Health Organization, Evian, France
20. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
21. Badesch D.B., Abman S.H., Ahearn G.S., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 suppl 1 (2004) 35S-62S
22. Galie N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
23. Laughlin V.V., Genthner D.E., Panella M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 273-277
24. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 132 (2000) 425-434
25. Maurer J.R., Frost A.E., Estenne M., et al. International guidelines for the selection of lung transplant candidates. J Heart Lung Transplant 17 (1998) 703-709
26. Channick R.N., Sitbon O., Barst R.J., et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 43 suppl (2004) 62S-67S
27. Keogh A.M., McNeil K.D., Wlodarczyk J., et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 26 (2007) 181-187
28. Simonneau G., Barst R.J., Galiè N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
29. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
30. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 4 (2002) 780-788
31. Oudiz R.J., Schilz R.J., Barst R.J., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126 (2004) 420-427
32. Gaine S.P., and Rubin L.J. Primary pulmonary hypertension. Lancet 352 (1998) 719-725
33. Raymond R.J., Hinderliter A.L., Willis P.W., et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39 (2002) 1214-1219
34. Schachna L., Wigley F.M., Chang B., et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 124 (2003) 2098-2104
35. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62 (2003) 1088-1093
36. Denton C.P., Cailes J.B., Phillips G.D., et al. Comparison of Doppler echocardiography and right heart catheterisation to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36 (1997) 239-243
37. Sanchez O., Humbert M., Sitbon O., et al. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 54 (1999) 273-277
38. Morelli S., Giordano M., and De Marzio P. Pulmonary arterial hypertension responsive to immunosuppressive treatment in SLE. Lupus 2 (1993) 367-369
39. Alpert M.A., Pressly T.A., Mukerji V., et al. Acute and long term effects of nifedipine on pulmonary and systemic haemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol 68 (1991) 1687-1691
40. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
41. Trad S., Amoura Z., Beigelman C., et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54 (2006) 184-191
42. Dorfmuller P., Humbert M., Perros F., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 38 (2007) 893-902
43. Trulock E.P., Edwards L.B., Taylor D.O., et al. Twentieth official adult lung and heart-lung transplant report-2003. J Heart Lung Transplant 22 (2003) 625-635
44. Schachna L., Medsger Jr. T.A., Dauber J.H., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 54 (2006) 3954-3961
45. Trulock E.P., Edwards L.B., Taylor D.O., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 24 (2005) 956-967